<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858403</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-15656</org_study_id>
    <secondary_id>CA180214</secondary_id>
    <nct_id>NCT00858403</nct_id>
  </id_info>
  <brief_title>Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation</brief_title>
  <official_title>Phase II Study of Dasatinib in Advanced Non-small Cell Lung Cancer With Ex Vivo and In Vivo Assessment of Tumor Target Modulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn how patients with Advanced Non-Small Cell Lung&#xD;
      Cancer (NSCLC) respond to the study drug Dasatinib. The study drug, Dasatinib, has been&#xD;
      approved by the U.S. Food and Drug Administration (FDA) for treatment of leukemia, but has&#xD;
      not been approved for the treatment of other kinds of cancer. The use of Dasatinib in this&#xD;
      study is considered experimental.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cycle 1 Day 1 (C1D1): Patients will have complete history and physical (H&amp;P), complete blood&#xD;
      count (CBC), complete metabolic panel (CMP) and electrocardiogram (EKG) on day 1. Each cycle&#xD;
      is 28 days. The C1D1 EKG can be omitted if the patient has no new cardiac symptoms and has&#xD;
      not starting taking any medication known to affect QT corrected for heart rate (QTc)&#xD;
      prolongation. Any residual toxicity from prior therapy for cancer will be recorded. Blood&#xD;
      will be drawn for assessment of serum markers. The patient will begin dasatinib at the&#xD;
      starting C1D1 on a daily basis.&#xD;
&#xD;
      Cycle 1 Day 10-20 (C1D10-20): Patients will have a second biopsy to obtain additional tumor&#xD;
      material to examine biological effects of dasatinib on signaling pathways. Dasatinib will be&#xD;
      taken first thing in the morning and the patient will log the time. Blood will also be drawn&#xD;
      for pharmacokinetic assessments of dasatinib levels in plasma and the time recorded. Four FNA&#xD;
      aspirates and 2 core biopsies can be obtained either at the bedside for palpable lesions or&#xD;
      through appropriate image-guided techniques (CT or US) at the discretion of the treating&#xD;
      physician in consultation with radiology. The time of the biopsy will be recorded. One core&#xD;
      biopsy should be immediately fixed in formalin and the other core biopsy should be snap&#xD;
      frozen in liquid nitrogen.&#xD;
&#xD;
      Cycle 2 Day 1 (C2D1): Patients will be seen by the treating physician and have complete H&amp;P,&#xD;
      CBC, and CMP. Blood will be drawn for assessment of serum markers. Toxicity of dasatinib will&#xD;
      be assessed. The patient will continue to take daily doses of dasatinib on a daily basis.&#xD;
&#xD;
      Cycle 2 Day 22 (C2D22): Patients will undergo reevaluation for tumor measurements. This&#xD;
      assessment can occur on C2D22 ±7 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual&#xD;
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participant Progressors vs. Non-progressors With Tumor Response</measure>
    <time_frame>1 year, 4 months</time_frame>
    <description>We planned to assess whether the extent of inhibition of extracellular signal-regulated protein kinase (ERK) phosphorylation in lung cancer cells exposed ex vivo to dasatinib significantly differed between patients categorized as progressors or non-progressors through standard Response Evaluation Criteria In Solid Tumors (RECIST)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response to Dasatinib</measure>
    <time_frame>1 year, 4 months</time_frame>
    <description>We planned to estimate the single agent response rate to dasatinib in this patient population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Progression Free Survival (PFS) at 6 Months</measure>
    <time_frame>1 year, 4 months</time_frame>
    <description>We planned to estimate the 6 month progression free survival rate of dasatinib in this patient population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>1 year, 4 months</time_frame>
    <description>We evaluated toxicity of dasatinib in this patient population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant Progressors vs. Non-Progressors With Inhibition Response</measure>
    <time_frame>1 year, 4 months</time_frame>
    <description>We planned to assess whether the extent of inhibition of proto-oncogene tyrosine-protein kinase (SRC) and protein kinase B (Akt) phosphorylation in lung cancer cells exposed ex vivo and in vivo to dasatinib significantly differs between patients categorized as progressors or non-progressors through standard RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Extent of Inhibition and Concentration of Dasatinib</measure>
    <time_frame>1 year, 4 months</time_frame>
    <description>We planned to explore whether the extent of inhibition of ERK, SRC and Akt phosphorylation in lung cancer cells exposed ex vivo to dasatinib will correlate with the drug concentration of dasatinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Mutation and Inhibition and to Disease Control Rate and Response</measure>
    <time_frame>1 year, 4 months</time_frame>
    <description>To analyze Kras and epidermal growth factor receptor (EGFR) mutation and their correlation to the ERK pathway inhibition and to disease control rate and response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment with Dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib 140 mg orally (po) every day starting Day #1, continuous dosing. This dose was chosen based on the current experience in patients with solids tumors who have had prior chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Take tablets of Dasatinib by mouth once a day.</description>
    <arm_group_label>Treatment with Dasatinib</arm_group_label>
    <other_name>SPRYCEL®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically documented diagnosis of NSCLC that is&#xD;
             advanced/metastatic (Stage IIIB/IV).&#xD;
&#xD;
          -  Performance Status (ECOG) 0-2&#xD;
&#xD;
          -  Previous chemotherapy with the exception of dasatinib. Patients who have had any type&#xD;
             of previous chemotherapy regimens for non-small cell lung cancer are eligible.&#xD;
&#xD;
          -  Adequate Organ Function:&#xD;
&#xD;
               -  Total bilirubin &lt; 2.0 times the institutional Upper Limit of Normal (ULN)&#xD;
&#xD;
               -  Hepatic enzymes (AST, ALT ) ≤ 2.5 times the institutional ULN&#xD;
&#xD;
               -  Serum Na, K+, Mg2+, Phosphate and Ca2+≥ Lower Limit of Normal (LLN)&#xD;
&#xD;
               -  Serum Creatinine &lt; 1.5 time the institutional ULN&#xD;
&#xD;
               -  Hemoglobin, Neutrophil count, Platelets, prothrombin time (PT), partial&#xD;
                  thromboplastin time (PTT) all Grade 0-1&#xD;
&#xD;
          -  Ability to take oral medication&#xD;
&#xD;
          -  Concomitant Medications:&#xD;
&#xD;
               -  Agree to discontinue St. Johns Wort while receiving dasatinib therapy&#xD;
&#xD;
               -  Agree that IV bisphosphonates will be withheld for the first 8 weeks of dasatinib&#xD;
                  therapy due to risk of hypocalcemia.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP):&#xD;
&#xD;
               -  A negative serum or urine pregnancy test within 72 hours prior to the start of&#xD;
                  study drug administration&#xD;
&#xD;
               -  Persons of reproductive potential must agree to use and utilize an adequate&#xD;
                  method of contraception throughout treatment and for at least 4 weeks after study&#xD;
                  drug is stopped Prior to study enrollment.&#xD;
&#xD;
          -  Signed written informed consent including a HIPAA form according to institutional&#xD;
             Guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No malignancy [other than the one treated in this study] which required radiotherapy&#xD;
             or systemic treatment within the past 5 years.&#xD;
&#xD;
          -  Prior dasatinib therapy.&#xD;
&#xD;
          -  Concurrent medical condition which may increase the risk of toxicity, including:&#xD;
&#xD;
               -  Patients with severe pulmonary disease that increases the risk of toxicity&#xD;
                  related to dasatinib-induced pleural effusions. This includes chronic obstructive&#xD;
                  pulmonary disease or pleural effusions (malignant or benign) requiring chronic&#xD;
                  oxygen therapy or patients that have had prior pneumonectomy. Patients that have&#xD;
                  a pulmonary embolism and require oxygen therapy will be excluded but not those&#xD;
                  patients who have a pulmonary embolism but do not require oxygen therapy.&#xD;
                  Patients with active pleural effusions not controlled with pleurodesis will be&#xD;
                  excluded.&#xD;
&#xD;
          -  Cardiac Symptoms; any of the following should be considered for exclusion:&#xD;
&#xD;
               -  Uncontrolled angina, congestive heart failure or MI within (6 months)&#xD;
&#xD;
               -  Diagnosed congenital long QT syndrome&#xD;
&#xD;
               -  Any history of clinically significant ventricular arrhythmias (such as&#xD;
                  ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)&#xD;
&#xD;
               -  Prolonged QTc interval on pre-entry electrocardiogram (&gt; 450 msec)&#xD;
&#xD;
               -  Patients with hypokalemia or hypomagnesemia if it cannot be corrected prior to&#xD;
                  dasatinib administration&#xD;
&#xD;
          -  History of significant bleeding disorder unrelated to cancer, including:&#xD;
&#xD;
               -  Diagnosed congenital bleeding disorders&#xD;
&#xD;
               -  Diagnosed acquired bleeding disorder within one year&#xD;
&#xD;
               -  Ongoing or recent (≤ 3 months) significant gastrointestinal bleeding&#xD;
&#xD;
          -  Concomitant Medications, any of the following should be considered for exclusion:&#xD;
&#xD;
               -  Category I drugs that are generally accepted to have a risk of causing Torsades&#xD;
                  de Pointes including: (Patients must discontinue drug 7 days prior to starting&#xD;
                  dasatinib)&#xD;
&#xD;
                    1. quinidine, procainamide, disopyramide&#xD;
&#xD;
                    2. amiodarone, sotalol, ibutilide, dofetilide&#xD;
&#xD;
                    3. erythromycin, clarithromycin&#xD;
&#xD;
                    4. chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide&#xD;
&#xD;
                    5. cisapride, bepridil, droperidol, methadone, arsenic, chloroquine,&#xD;
                       domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin,&#xD;
                       lidoflazine.&#xD;
&#xD;
          -  Women:&#xD;
&#xD;
               -  unwilling or unable to use an acceptable method to avoid pregnancy for the entire&#xD;
                  study period and for at least 4 weeks after cessation of study drug,or&#xD;
&#xD;
               -  have a positive pregnancy test at baseline&#xD;
&#xD;
               -  pregnant or breastfeeding&#xD;
&#xD;
          -  Prisoners or persons who are compulsorily detained (involuntarily incarcerated)for&#xD;
             treatment of either a psychiatric or physical (e.g., infectious) illness&#xD;
&#xD;
          -  Patients on systemic anticoagulation at risk of bleeding related to tumor biopsy that&#xD;
             cannot be off anticoagulation per the discretion of their physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Haura, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <results_first_submitted>July 12, 2011</results_first_submitted>
  <results_first_submitted_qc>August 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2011</results_first_posted>
  <last_update_submitted>December 13, 2013</last_update_submitted>
  <last_update_submitted_qc>December 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Non-small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment With Dasatinib</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment With Dasatinib</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 40 and 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 60 and 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 70 and 79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participant Progressors vs. Non-progressors With Tumor Response</title>
        <description>We planned to assess whether the extent of inhibition of extracellular signal-regulated protein kinase (ERK) phosphorylation in lung cancer cells exposed ex vivo to dasatinib significantly differed between patients categorized as progressors or non-progressors through standard Response Evaluation Criteria In Solid Tumors (RECIST)</description>
        <time_frame>1 year, 4 months</time_frame>
        <population>The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Dasatinib</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant Progressors vs. Non-progressors With Tumor Response</title>
          <description>We planned to assess whether the extent of inhibition of extracellular signal-regulated protein kinase (ERK) phosphorylation in lung cancer cells exposed ex vivo to dasatinib significantly differed between patients categorized as progressors or non-progressors through standard Response Evaluation Criteria In Solid Tumors (RECIST)</description>
          <population>The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response to Dasatinib</title>
        <description>We planned to estimate the single agent response rate to dasatinib in this patient population</description>
        <time_frame>1 year, 4 months</time_frame>
        <population>The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Dasatinib</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response to Dasatinib</title>
          <description>We planned to estimate the single agent response rate to dasatinib in this patient population</description>
          <population>The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Progression Free Survival (PFS) at 6 Months</title>
        <description>We planned to estimate the 6 month progression free survival rate of dasatinib in this patient population.</description>
        <time_frame>1 year, 4 months</time_frame>
        <population>We were able to assess 4 of the 7 participants at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Dasatinib</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression Free Survival (PFS) at 6 Months</title>
          <description>We planned to estimate the 6 month progression free survival rate of dasatinib in this patient population.</description>
          <population>We were able to assess 4 of the 7 participants at 6 months.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <description>We evaluated toxicity of dasatinib in this patient population.</description>
        <time_frame>1 year, 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Dasatinib</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <description>We evaluated toxicity of dasatinib in this patient population.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant Progressors vs. Non-Progressors With Inhibition Response</title>
        <description>We planned to assess whether the extent of inhibition of proto-oncogene tyrosine-protein kinase (SRC) and protein kinase B (Akt) phosphorylation in lung cancer cells exposed ex vivo and in vivo to dasatinib significantly differs between patients categorized as progressors or non-progressors through standard RECIST criteria.</description>
        <time_frame>1 year, 4 months</time_frame>
        <population>The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Dasatinib</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant Progressors vs. Non-Progressors With Inhibition Response</title>
          <description>We planned to assess whether the extent of inhibition of proto-oncogene tyrosine-protein kinase (SRC) and protein kinase B (Akt) phosphorylation in lung cancer cells exposed ex vivo and in vivo to dasatinib significantly differs between patients categorized as progressors or non-progressors through standard RECIST criteria.</description>
          <population>The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Extent of Inhibition and Concentration of Dasatinib</title>
        <description>We planned to explore whether the extent of inhibition of ERK, SRC and Akt phosphorylation in lung cancer cells exposed ex vivo to dasatinib will correlate with the drug concentration of dasatinib.</description>
        <time_frame>1 year, 4 months</time_frame>
        <population>The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Dasatinib</title>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Extent of Inhibition and Concentration of Dasatinib</title>
          <description>We planned to explore whether the extent of inhibition of ERK, SRC and Akt phosphorylation in lung cancer cells exposed ex vivo to dasatinib will correlate with the drug concentration of dasatinib.</description>
          <population>The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Mutation and Inhibition and to Disease Control Rate and Response</title>
        <description>To analyze Kras and epidermal growth factor receptor (EGFR) mutation and their correlation to the ERK pathway inhibition and to disease control rate and response.</description>
        <time_frame>1 year, 4 months</time_frame>
        <population>The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Dasatinib</title>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Mutation and Inhibition and to Disease Control Rate and Response</title>
          <description>To analyze Kras and epidermal growth factor receptor (EGFR) mutation and their correlation to the ERK pathway inhibition and to disease control rate and response.</description>
          <population>The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 4 months</time_frame>
      <desc>From first participant on study date to last participant off study date.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment With Dasatinib</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <description>Grade 4 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 3 - probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fever in absence of neutropenia</sub_title>
                <description>Grade 2 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <description>Grade 3 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death Due to Disease Progression</sub_title>
                <description>Grade 5 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 4 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 3 - probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>Grade 4 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema - Limb</sub_title>
                <description>Grade 1 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hemoglobin - Anemia</sub_title>
                <description>Grade 2 - probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <description>Grade 1 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Grade 1 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 1 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea - Intermittent</sub_title>
                <description>Grade 2 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting - Intermittent</sub_title>
                <description>Grade 2 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdomen Pain</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Grade 1 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Grade 1 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 2 - probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 1 - probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <description>Grade 1 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Grade 2 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea - Intermittent</sub_title>
                <description>Grade 1 - probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Voice Hoarseness</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Grade 1 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Grade 2 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <description>Grade 2 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>Grade 1 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Grade 1 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 1 - related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 3 - related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 1 - probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 2 - related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea - With Exertion</sub_title>
                <description>Grade 2 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hemorrhage - Hemoptysis</sub_title>
                <description>Grade 1 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pleural Effusion - Intermittent</sub_title>
                <description>Grade 2 - related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Eric Haura, M.D., via Moffitt Cancer Center</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-6827</phone>
      <email>eric.haura@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

